Slušaj GRACEcast podkast

FCR vs. BR - Is One Better?	GRACEcast	04:23
Basics of Small Cell Lung Cancer	GRACEcast	04:55
Adjuvant Chemotherapy for Elderly and Frail Patients	GRACEcast	06:30
Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1	GRACEcast	05:28
New Trials of Targeting Therapies to Treat Leptomeningeal Carcinomatosis	GRACEcast	04:31
ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments	GRACEcast	04:59
Immuno-oncology Developments - Combinations and Use as First-Line Therapy	GRACEcast	07:11
Does Current Evidence Support Favoring Proton-Beam Radiation	GRACEcast	08:36
J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?	GRACEcast	11:02
Are There Less Toxic Alternatives to the Extreme Regimen	GRACEcast	04:06
Promising Early Data for Oral Inhibitor Buparlisib	GRACEcast	01:55
Using Immunotherapy as First-Line Treatment and in Combinations	GRACEcast	04:36
Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients	GRACEcast	04:17
Using Biomarkers in Immunotherapy	GRACEcast	02:04
Common Side Effects of PD-1 Inhibitors	GRACEcast	04:16
Data from Keynote 12 Nivolumab and Pembrolizumab	GRACEcast	04:11
How Promising Are The Results From Checkmate 141?	GRACEcast	02:58
Local Consolidation Therapies for Oligomatastases	GRACEcast	12:31
The Immune System and PD-1 Inhibitors	GRACEcast	01:45
Urine or Blood Testing Instead of Lung Biopsy Shows Promise for Finding EGFR Mutations	GRACEcast	08:29
Can Online Patient Groups Speed New Targeted Therapies?	GRACEcast	04:47
Rova-T Shows Promise in Small Cell Lung Cancer	GRACEcast	04:58
Significance Of IGHV Mutations & How They Are Assessed	GRACEcast	02:49
Immunotherapy Combinations	GRACEcast	04:35
Immunotherapy as First-Line Treatment	GRACEcast	03:46
Lung Cancer Screening - Process and Potential Benefits	GRACEcast	06:19
Bronchoscopy and EBUS	GRACEcast	05:54
Maintenance Therapy for Advanced NSCLC	GRACEcast	04:35
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC	GRACEcast	05:20
Are There Clinically Significant Distinctions Between PD-1 and PD-L1?	GRACEcast	03:29
Histology-Specific Recommendations - Large-Cell Neuroendocrine	GRACEcast	02:24
Histology-Specific Regimens - Squamous	GRACEcast	04:02
Histology-Specific Regimens - Adenocarcinoma	GRACEcast	02:53
What is the Role of Bevacizumab in Stage IV NSCLC?	GRACEcast	03:46
Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment	GRACEcast	03:40
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance	GRACEcast	02:20
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy	GRACEcast	02:30
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC	GRACEcast	02:00
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements	GRACEcast	00:56
ROS-1 Rearrangements: What Are They?	GRACEcast	01:53

FCR vs. BR - Is One Better?

GRACEcast

04:23

Basics of Small Cell Lung Cancer

GRACEcast

04:55

Adjuvant Chemotherapy for Elderly and Frail Patients

GRACEcast

06:30

Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1

GRACEcast

05:28